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Abstract
Zygomycosis (mucormycosis) is being increasingly recognized as causing infection in recent years. National and multinational European
surveys attempting to analyse the epidemiological parameters of this potentially devastating infection are very few. Although the exact
incidence could not be deﬁned due to the different methodologies used in these studies and the absence of a denominator, there were
some useful observations made regarding the clinical presentation, sites of infection and diagnostic practices. Moreover, the importance for
a prompt and accurate diagnosis has been stressed. As early diagnosis can signiﬁcantly affect the initiation of treatment and decrease
mortality, future research should focus on the development of an epidemiological risk assessment tool and novel diagnostic methods.
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Introduction
Zygomycosis (mucormycosis) is a rare but emerging fungal
infection worldwide, with high morbidity and mortality. It
includes infections due to fungi of the order Mucorales, as well
as of the order Entomophthorales. As the latter constitute
completely different clinical entities predominantly found in
immunocompetent patients in tropical and subtropical areas,
they will not be discussed in this review. The term mucormy-
cosis is more appropriate, but as the term zygomycosis has
been used in the past, unavoidably both terms will be used
interchangeably in the manuscript. Mucormycosis has gained
importance in Europe in recent years, and a Working Group
on zygomycosis was formed by the European Confederation of
Medical Mycology (ECMM) in 2004. The aim of the working
group was to analyse the clinical characteristics, microbiology,
treatment practices and outcome of zygomycosis in Europe
through a voluntary case registry, because no large prospective
studies had been undertaken until then. Despite the pro-
gresses made in the understanding of pathogenesis and the
therapeutic approach of this infection, many questions are still
unanswered and the case fatality rate remains unacceptably
high. This review summarizes what we have learned from the
most representative epidemiological studies conducted in
Europe (Table 1) and discusses what is more to achieve in
future research.
Incidence
Only a few European studies have focused on the incidence of
mucormycosis, but no exact incidence rates are feasible due to
the absence of a commonly accepted denominator. In a large
national multicentre 10-year-study, Bitar et al. [1] provided a
population-based estimate of zygomycosis incidence and
trends in France. They showed an increasing incidence from
0.7 per million in 1997 to 1.2 per million in 2006 (p < 0.001).
As a denominator, they used the total population based on a
national census and also took into account geographic
variations for the analysis. This, however, was a retrospec-
tive study using data extraction codes, according to the
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International Classiﬁcation of Diseases, 10th revision (ICD-10)
from hospital information systems. This method has limita-
tions, mainly related to difﬁculties encountered with the
diagnosis of the infection in clinical practice.
Further estimates derive from monocentric studies, one
from Belgium [2] and one from Switzerland [3]. Saegeman
et al. [2] found a signiﬁcant increase in the speciﬁc annual
incidence rate in a large university hospital in Leuven, from
0.019 cases per 10 000 patient-days in 2000 to 0.148 cases per
10 000 patient-days in 2009. Annual incidence rate was deﬁned
as the number of mucormycosis cases per risk group over the
number of risk patients per year. The ﬁndings were based on
retrieved culture and pathology data and not on ICD codes, in
an also 10-year retrospective study. However, the determina-
tion of patients belonging to the risk groups was based on ICD
codes (9th Revision). These authors, to further explain this
incidence increase, examined the possibility that the cause was
the prophylactic use of voriconazole in high-risk patients, as
some studies suggested [4,5]. They showed that there was no
relation to the prior use of voriconazole, and most probably
the increase was associated with the increasing number of
patients with underlying haematologic malignancy.
Ambrosioni et al. [3] observed an increase in mucormy-
cosis cases at the University of Geneva Hospitals from 0.57
before 2003 to 6.3 per 100 000 admissions per year after
2003. They concluded that the increase in their institution
was probably multifactorial, but a temporal relationship was
established with the extended use of voriconazole and
caspofungin in association with an increase in immunocom-
promised patients.
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FIG. 1. Distribution of underlying diseases according to study. ‘Other’ represents risk factors such as solid organ transplantation, HIV/AIDS,
treatment with corticosteroids, deferoxamine and dialysis. *Data of only six cases. **Possible bias due to the nature of the study.
TABLE 1. Overview of the main European studies on mucormycosis
Study Period Study category
No of
patients Incidence Laboratory diagnosis Case fatality rates %
Petrikkos [12]
Greece
1993–2002 1 centre
retrospective
24 nd Histopathology or culture 54
Torres-Narbona [6]
Spain
2005 Multicentre
prospective
6 0.43/106 inhab. or 0.62/105
hosp. admissions in 2005
Histopathology culture nd
Bitar [1]
France
1997–2006 Multicentre
retrospective
531 Increase 0.7/106 inhab. in
1997 to 1.2/106 inhab. in 2006
nd 47.8–4.2 according to
underlying disease
Lanternier [11]
France
2005–2007 Multicentre
retrospective
101 nd Histopathology or culture
+molecular
44 total 22–79 (according
to body site)
Saegeman [2]
Belgium
2000–2009 1 centre
retrospective
31 Increase 0.019/104
patient-days in 2000 to
0.148/104 patient-days in 2009
Histopathology or culture 11–60, (according to
underlying disease)
Ambrosioni [3]
Switzerland
1989–2008 1 centre
retrospective
19 Increase Histopathology or culture
+molecular
65 overall 48 attributed
Pagano [7]
Italy
2004–2007 Multicentre
prospective
60 nd Histopathology or culture 53 total 73 antifungals only
14 antifungals + surgery
Skiada [8]
ECMM
2005–2007 Multicentre 230 nd Histopathology culture
molecular
32 attributed 36 ID 22
non-ID
nd, not deﬁned; ECMM, European Confederation of Medical Mycology.
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Torres-Narbona et al. [6] in a multicentre study with the
participation of 36% of hospitals throughout Spain estimated an
incidence of 0.43 cases per million inhabitants per year and
0.62 cases per 100 000 hospital admissions.
None of the other two multicentre prospective studies
analysed here, one national survey from Italy and the ECMM
Working Group on Zygomycosis study [7,8], were designed to
make incidence estimates.
Underlying Conditions and Clinical Forms
In most studies [2,3,6–8], cases were categorized as proven or
probable using the deﬁnitions for invasive fungal disease of the
European Organization for Research and Treatment of Can-
cer/Invasive Fungal Infections Cooperative Group; National
Institute of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group [9], or the revised
version [10] for studies after 2009. In the ECMM study, the
host criteria were modiﬁed and included diabetes mellitus [8].
The main underlying diseases and conditions were (i) haema-
tological malignancies including hematopoietic stem cell trans-
plantation (HSCT), (ii) other malignancies, solid organ
transplantation and other immune deﬁciencies such as HIV/
AIDS, renal insufﬁciency, liver cirrhosis and high dose steroids,
(iii) diabetes mellitus and (iv) trauma, including secondary to
accidents, major surgery and burns. The distribution varied
between studies (Fig. 1), reﬂecting the different design and
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FIG. 2. Distribution of clinical presentation according to study. The most prominent clinical forms are presented. ‘Others’ represents
gastrointestinal or solitary organ infection (brain, heart, kidney, peritoneum, liver, biliary tract and spleen). ‘Disseminated’ represents infection with
concurrent involvement of at least two noncontiguous organ sites of the body. *Data of only six cases. **Possible bias due to the nature of the
study.
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FIG. 3. Distribution of infectious agents according to study.
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methodology used. Haematologic malignancy was the most
prominent underlying disease in most of the studies, ranging
between 38 and 62%. In the study of Bitar et al. [1], the
proportion was much lower, but this can be explained by the
limitations of the study mentioned above. A considerable
number of patients had more than one underlying risk factor,
such as haematologic malignancy and diabetes, which ranged
from 12 to 33% [3,6–8].
The clinical presentation and site of infection also varied
(Fig. 2). Four studies provided data for the association of this
parameter with the underlying disease [6,8,11,12]. It appears
that the sinus localization (rhino or rhino-orbital or rhino-orb-
ito-cerebral form) is most prominent in diabetes patients and
the pulmonary localization in haematological patients. Patients
with trauma or no obvious risk factor are usually affected by
cutaneous mucormycosis.
Only one study [11] reports the time elapsed between ﬁrst
symptoms and diagnosis. This was 2 weeks (median), with a
range of 0–30 weeks. More speciﬁcally, it was 1 week for
patients with HSCT and patients with trauma (range 1–30 and
0–16, respectively), 2 weeks for haematological malignancy
(range 0–25), 3 weeks (range 1–18) for those with diabetes
and 6 weeks (range 3–20) for solid organ transplantation. The
time between ﬁrst symptoms and diagnosis was signiﬁcantly
shorter in patients with cutaneous mucormycosis (1 week,
range 0–3) than in those presenting with rhinocerebral
localization (3 weeks, range 1–18), pulmonary (2 weeks, range
0–20) or disseminated disease (2.5 weeks, range 1–25).
Laboratory Diagnosis
Diagnosing zygomycosis is challenging. The diagnosis relies on
the evidence of tissue invasion and is made on tissue sections
showing the characteristic hyphae of the fungus with accompa-
nying acute suppurative inﬂammation, with focal areas of
granulomatous inﬂammation [13]. Cultures allow not only the
diagnosis, but also the identiﬁcation to species level and
eventually the antifungal susceptibility testing. Cultures, how-
ever, are not always feasible due to a number of reasons,
including inappropriate sampling or inappropriate storage of the
sample until examined [13].On the other hand, a positive culture
does not alwaysmean infection, as these organisms are common
in the environment. Therefore, growth from nonsterile body
sites is not itself diagnostic, and it should be always evaluated
together with clinical and histopathological data. Bitar et al. [1]
commented that the many gastrointestinal cases reported in the
hospital information system they used may have been false-po-
sitive cases resulting from laboratory contamination. As they
state, the unusual distribution of clinical presentations found in
their study and the fact that one-third of clinical information was
missing, favour this hypothesis. In the study of Torres-Narbona
et al. [6], zygomycosis was conﬁrmed only in 7.7% (N = 6) of the
patients with positive cultures. In the Swiss study, 65% of the
patients (36/55) were considered as colonized without any
evidence of invasive disease [3].
In the RetroZygo French study [11], 68 of 101 proven and
probable mucormycosis cases had positive cultures. These
were obtained from 48%, 68% and 95% for rhinocerebral,
pulmonary and cutaneous localization, respectively. In the
Italian study [5], the diagnosis of 14 patients of 60 relied only
on histology (77% positive cultures). The sensitivity however
of culture cannot be estimated by these European studies due
to missing data. For example, in the RetroZygo study [11], 55%
of the patients with positive histology had also a positive
culture, but it is not clear whether a culture had always been
performed.
In the ECMM study of Skiada et al. [8], methods varied
among the participating centres. Histopathology was per-
formed in 148 of the 230 cases (64%) either alone or in
combination with another method such as culture. The
responsible pathogen was isolated from cultures in 172 cases
(75%). In 35 cases (15%), culture was the only method used.
Direct examination was performed in 128 cases (56%). In
another ﬁve cases (2%), the diagnosis was made by tissue PCR.
As prompt diagnosis is very important and affects the
survival of the patient [14], a direct microscopical examination
of tissue mount with KOH 10% and preferably with an optical
brightener such as calco-ﬂuor white or Blankophor is of great
value. None of the studies speciﬁcally reported data from
direct microscopy and time elapsed between laboratory
diagnosis and therapy initiation.
Infecting Agents
Few studies provide detailed data about the species involved.
Petrikkos et al. [12] (Fig. 3) reported that eight of their 24 patients
were infected with Rhizopus spp. and 16 with Mucor spp. The
term ‘Mucor’ probably does not always represent some species
of the Mucor genus as, especially in older studies, the tendency
was to designate an unknown mucoralean fungus as ‘Mucor’.
In the Spanish study, only four of the six strains were
identiﬁed: two Mucor, one Rhizomucor and one Cunninghamella
bertholletiae [4].
In the French [1] and Belgian [2] studies, there was no
mention of involved fungi, but in a second nationwide French
study, the RetroZygo study [11], which merged data from two
notiﬁcation systems between 2005 and 2007, mycological data
based exclusively on molecular identiﬁcation were presented.
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The three main fungal species identiﬁed in a total of 59 patients
were Rhizopus oryzae (R. arrhizus) 32%, Lichtheimia sp.
(formerly Absidia or Mycocladus, 29%) and Rhizopus microsporus
(17%). Other organisms were Rhizomucor pusillus, Saksenaea
vasiformis, Cunninghamella sp., Mucor circillenoides and Apophy-
somyces elegans, in very low numbers (1–4 isolates). Notably,
Rhizopus oryzae was present in 85% of rhinocerebral forms,
compared with only 17% of nonrhinocerebral forms. None of
the other studies analysed the distribution of infecting agents
according to the underlying disease or site of infection. It can
only be deducted from data presented by two further studies
[3,6].
In the Swiss study [3], 42% (N = 8) of the isolates were
identiﬁed as Rhizopus sp., 32% (N = 6) Rhizomucor, 16%
(N = 3) Absidia (Lichtheimia), 5% (N = 1) Cunninghamella, and
5% (N = 1) Mucor. Although also molecular methods were
used in that study after 2001, only the genus name was
reported.
In the Italian study [5], 15 of the cultured strains were
Rhizopus sp., six Rhizomucor, ﬁve Absidia (Lichtheimia) corymbif-
era, two were Cunninghamella sp., whereas 18 (30%) were not
speciated and reported as ‘Mucorales’.
In the ECMM study [8], the most prominent infecting
organisms were of the genus Rhizopus (58 of the 172 available
culture results) representing 34%, followed by species of Mucor
and Lichtheimia (33 and 32 isolates, respectively), representing
19% each.
Mortality
Case fatality rates (CFR) varied in the different studies and also
according to different underlying conditions and localization,
with much higher rates among patients with haematologic
malignancies, disseminated infection and antifungal therapy
alone.
Petrikkos et al. [12] found 54% mortality, as 13 of the 24
patients died. In the study of Bitar et al. [1], the speciﬁc CFR
according to underlying conditions was calculated only for
deaths for which information was available. It was greater for
patients with haematologic malignancies (47.8%, 11/23) or
bone marrow transplantation (36.4%, 12/33). In patients with
nonhaematologic immunosuppression, diabetes, or no known
risk factors, the CFRs were 12.5% (8/64), 9.3% (8/86) and 4.2%
(12/289), respectively.
In the study of Lanternier et al. [11], the mortality rate of
the 101 cases at day 90 was 44% and differed signiﬁcantly
according to localization; it was 25%, 79%, 48%, and 22% in
rhinocerebral, disseminated, pulmonary and cutaneous infec-
tions, respectively. Mortality was higher for disseminated
forms compared with rhinocerebral, pulmonary or skin
localization. Among patients with rhinocerebral localizations,
the 90-day mortality was 56% in cases of cerebral involvement
and 20% for sino-orbital forms, whereas no death was
observed for isolated sinusitis. The mortality rate was 60%,
32% and 11% in patients with haematological malignancies
(N = 50), diabetes mellitus (N = 9) and trauma (N = 18),
respectively. Patients with two underlying conditions or more
had a higher mortality rate than those with one or no risk
factors.
In Ambrosioni et al. [3], overall mortality was 53% (10/19),
with a mortality rate of 75% (9/12) in patients with antifungal
treatment alone, and 14% (1/17) in those receiving a combi-
nation of antifungal treatment and surgery.
In most of the studies, the overall mortality was reported.
Saegeman et al. [2] found a death rate of 65% among 31
patients with mucormycosis, whereas 48% was directly
attributable to the fungal infection. This appears to be much
higher than rates reported in the French study. They explained
that this discrepancy might have been merely a reﬂection of
differences in case deﬁnitions due to the nature of their study,
in which more stringent deﬁnitions were applied.
In the Italian study [7], the invasive fungal infection
attributable mortality was estimated through detailed case--
by-case analysis; an attributable mortality rate of 32% (19/60)
was registered, 36% (15/42) among immunocompromised and
22% (4/18) among immunocompetent patients, which was
reduced to 18% (8/44) when patients were treated with
L-AmB.
In the ECMM multinational survey [8], total mortality among
the 230 cases was 47%. The underlying disease with the highest
CFR was HSCT (76%, 13/17). For patients with haematologic
malignancies, the CFR was 52% (49/95). Furthermore, in the
ECMM study, patients with disseminated disease had the highest
mortality (58%, 18/31), followed by patients with pulmonary
disease (56%, 33/59). In patients with diabetes as the only
underlying disease, mortality was 44% (8/18) and the best
outcome was seen in immunocompetent patients (6%, 1/18).
Discussion
Mucormycosis is a global challenge. The estimation of its exact
incidence remains an elusive target, as it is very difﬁcult to have
a common denominator. Furthermore, the problems inherent
in the diagnosis of mucormycosis add to the difﬁculty of
obtaining a clear view of the epidemiology of this disease.
Patients are often treated presumptively for mucormycosis,
while cases may be missed due to lack of histological and
microbiological proof. The ﬁrst active population-based
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surveillance study was performed in San Francisco, California,
from 1992 to 1993, revealing that the annual incidence of
mucormycosis was 1.7 cases per 1 million individuals (c. 500
cases per year) [15]. This incidence is higher than those
reported in the more recent studies from Spain and France
[1,6]. It should be noted, however, that the San Francisco
study was performed in a selected, high-risk population, while
the two in Europe involved a more general one. The ﬁrst large
collection of case reports was published in 2005 by Roden
et al. [16]. The authors compiled 929 cases of mucormycosis
from 1885 to 2004 and showed that an increasing proportion
of immunocompromised patients with mucormycosis was
reported in the 1980s and 1990s. This could be explained by
the actual increase in the incidence of mucormycosis, the
increased awareness of the disease by physicians and of course
by publication bias. It is interesting that, although using very
different methods to analyse epidemiology, multiple studies
report an increase in the incidence of mucormycosis [1–3,17].
The underlying diseases are similar in all the studies reported
from Europe (Fig. 1), with the exception of the one by
Torres-Narbona et al. and the study by Bitar et al. In the ﬁrst
case, the number of patients was very small (six), while in the
latter, the methods used led to probable misidentiﬁcation of
cases. The epidemiological characteristics of this disease are
more precisely described when the study is focused on one
speciﬁc population. In the Prospective Antifungal Therapy
(PATH) alliance registry, a multicentre, prospective, observa-
tional study, the epidemiologic characteristics and outcomes of
invasive fungal infections were assessed in hematopoietic stem
cell transplant recipients from sixteen medical centres from
North America during a 3-year period [17]. A recent study
focused on the mucormycosis patients in the PATH alliance
registry and presented a descriptive analysis of 121 cases [18].
Registration of cases, despite the difﬁculties in implemen-
tation, is the only method to collect information about rare
diseases, such as mucormycosis. Initiatives, such as the
Fungiscope, a Global Registry for Emerging Fungal Infections,
have contributed signiﬁcantly to the current knowledge of rare
fungal infections including mucormycosis; in an article of 2010
[19], data from 41 zygomycosis cases from Europe and Asia
were analysed. In Europe, the largest registry for mucormy-
cosis is the one constructed by the previously ECMM and
currently ECMM/ISHAM Working Group on Zygomycosis
(www.zygomyco.net). The existence of a single European
registry can focus on clinical cases and mucoralean species
encountered in Europe and also ensure that cases are not
submitted in duplicate. The experience of the ﬁrst analysis of a
large amount of cases from Europe [8], except for the valuable
information on the epidemiology of this disease also high-
lighted the points for improvement in this endeavor, as in many
cases, data were incomplete and many questions still remain
unanswered. Its database, for example, could be expanded
with the exact molecular identiﬁcation of the organism
involved in each case. As accumulating knowledge shows
differences in the distribution of genera with respect to the
underlying condition or site of infection [11] and even
differences in antifungal susceptibility patterns [20], such
information is very important. The low survival rates reported
in all studies point to the need for further studies on
mucormycosis, aiming to improve diagnostic methods and
initiate the proper therapy earlier.
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